Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest from Andrew McConaghie
In the crowded and competitive field of generalized myasthenia gravis, Amgen has faith that Uplizna’s twice-yearly administration will make it the treatment of choice.
Evaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.
The REDEFINE 2 study saw CagriSema fail to outshine Lilly’s tirzepatide in weight loss for overweight patients with diabetes, leaving its rival still in the driving seat.
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
The MATTERHORN study could set Imfinzi up for another new perioperative use, even though the gastric cancer trial has yet to demonstrate an overall survival benefit.